Capecitabine and Paronychia - a phase IV clinical study of FDA data
We study 48,647 people who have side effects when taking Capecitabine. Paronychia is found, especially among people who are female, 60+ old, have been taking the drug for 1 - 6 months, also take Lapatinib and have Breast cancer.
The phase IV clinical study analyzes which people take Capecitabine and have Paronychia. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
48,647 people reported to have side effects when taking Capecitabine.
Among them, 153 people (0.31%) have Paronychia.
What is Capecitabine?
Capecitabine has active ingredients of capecitabine. Currently, eHealthMe is studying from 55,210 Capecitabine users.
What is Paronychia?
Paronychia (infection in the tissues adjacent to a nail on a finger or toe) is found to be associated with 1,274 drugs and 693 conditions by eHealthMe. Currently, we are studying 5,570 people who have Paronychia.
Number of Capecitabine and Paronychia reports submitted per year:
Time on Capecitabine when people have Paronychia *:
Gender of people who have Paronychia when taking Capecitabine*:
Age of people who have Paronychia when taking Capecitabine *:
Common drugs people take besides Capecitabine *:
Common side effects people have besides Paronychia *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Capecitabine and have Paronychia?Check whether Paronychia is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
- Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .
Capecitabine side effects by duration, gender and age:
- Capecitabine side effects (55,210 reports)
Paronychia treatments and more:
- Paronychia (5,570 reports)
Common drugs associated with Paronychia:
- Fluorouracil: 441 reports
- Oxaliplatin: 438 reports
- Gilotrif: 390 reports
- Vectibix: 284 reports
- Methotrexate: 182 reports
- Erbitux: 181 reports
- Prednisone: 181 reports
- Xeloda: 173 reports
- Capecitabine: 153 reports
- Docetaxel: 146 reports
All the drugs that are associated with Paronychia:
- Paronychia (1,274 drugs)
Common conditions associated with Paronychia:
- Colon cancer: 459 reports
- Lung cancer - non-small cell: 401 reports
- Rheumatoid arthritis: 246 reports
- High blood pressure: 226 reports
- Breast cancer: 215 reports
- Preventive health care: 208 reports
All the conditions that are associated with Paronychia:
- Paronychia (693 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on capecitabine (the active ingredients of Capecitabine) and Capecitabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Cardizem and Cipro drug interaction - 8 seconds ago
- Prednisone and Implant Site Discharge - 9 seconds ago
- Megace and Abdominal Pain - 12 seconds ago
- Tikosyn and Promethazine drug interaction - 18 seconds ago
- Megestrol Acetate and Sinemet drug interaction - 18 seconds ago
- Amlodipine and Laryngeal Discomfort - 20 seconds ago
- Mitoxantrone Hydrochloride and Enteritis Infectious - 22 seconds ago
- Co-Codamol and Tiotropium Bromide drug interaction - 31 seconds ago
- Zyprexa and Pain - 44 seconds ago
- Tapentadol and Humalog drug interaction - 48 seconds ago